YEAR EVENTS 1988 - The Company was incorporated on 8th July, with the objective of carrying on the business of manufacture and marketing of chemicals, intermediates, dyes, pharmaceuticals and pesticides. - Hikal Chemical Industries Limited (HCIL), jointly promoted by Surajmukhi Investment and Finance Limited, a wholly owned subsidiary of Kalyani Steels Limited and the Hiremath family. - The period from 1988 to 1991 was utilised in setting up the manufacturing facilities at Mahad over land admeasuring 27004 square metres. 1990 - On 28th February, HCIL became a deemed public company under the provisions of Section 43 A of the Companies Act, 1956, and a fresh Certificate of Incorporation was obtained from the Registrar of Companies. - The Company also proposes to enter the business of agrochemicals, more specifically pesticides, and commence production of Metoxuron (used as a wheat herbicide) and Metamitron (used as a sugar beet herbicide). 1991 - The Company has issued 1,50,000 shares of Rs.10/- each to Hiremath Chemicals Limited in lieu of technical know-how and engineering in the year. - The Memoranum of Understanding (MOU) dated 3rd January, valid for a period of 7 years, between Hikal Chemical Industries Ltd. and Hiremath Chemicals Ltd. covers transfer of technology and technical assistance for Meta chloro aniline, 3,4 DCNB and paracumidine. 1993 - In December, Sumitomo Corporation, Japan, one of the world's largest trading houses, with assets of U.S. $ 46,402 million and Net Income of U.S. $ 176 million acquired an equity stake in the Company. Sumitomo has interests in commodities, industrial and consumer goods. - Hikal was the first chemical company in India in which Sumitomo Corpn. has taken equity in 1993 with a 3.62% share. - Agreement dated 30th September, entered into between the Company and Mr. Jai. Hiremath on his appointment as the Managing Director of the Company. 1994 - The Company subsequently became full fledged Public Limited Company by passing a special resolution in the E.G.M. held on 7th July. Revised certificate of incorporation has been obtained on 16th September. - In order to part finance the expansion-cum-diversification programme, the company had successfully made a public issue of 7,50,000 equity shares of Rs.10/- each at a premium of Rs. 40/- in October. The public issue received over whelming response from the investors and the offer made to the public was oversubscribed by 21.48 times. 1995 - The company has successfully completed the expansion of the Meta Chloro Aniline and Para Cumidine Plants. - The company has also undertaken diversification in the field of Agro Chemicals and has started production of Metoxuron and has entered into a long term exclusive contract with Searle (India) Ltd. - The company issued 593926 bonus shares in the ratio of 1 equity share for every 2 equity shares held in July by apitalising free reserves of Rs. 59.39 lacs. - The company issued 445722 equity shares of Rs. 10 each and 22500 equity shares of Rs. 10 each for cash at par on rights and preferential basis respectively in July. - New products will be introduced to improve the profitability of the Company. 1996 - Metoxuron plant was successfully commissioned and after trial runs commercial production commenced during March. - The company maintained the highest standards of safety. Effective effluent treatment plant & environment care were the top priorities. 1997 - Hikal Chemicals Industries Limited is engaged in the production of chemicals used by the pharmaceuticals, agro chemicals and dye industries. - The company has also launched Metoxuron a technical wheat herbicide. For this product the company has entered into a agreement with Searle India, which will buy it for a period of five years. - The company has issued 4,00,000 14% Non Convertible Cumulative Redeemable Preference Shares of Rs. 100/- each on 28th October, for 3 years to IDBI Bank Ltd. - The company has allotted 14,66,700 equity shares of Rs. 10/- each, at premium of Rs. 35/- on 26th December, to promoters & Sumitomo Corporation, Japan on Preferential allotment basis. 1998 - The company has appointed a representative in England to indentify our efforts to increase export. - The company has entered into a 10 year agreement with Merck & Co. Inc., U.S.A. for exclusive supply of Thiabendazole on 100% buy back arrangement. 1999 - The promoters of Hikal Chemicals Industries Ltd (HCIL) and the Kalyani group, through their subsidiary, are making an unconditional cash open offer to all equity shareholders of Hikal Chemicals Industries Ltd (HCIL) to purchase 50,300 shares of Rs 10 each at Rs 45 per fully paid up share. - Hikal is the only company in the world which manufactures TBZ and the plant has been set up with the technical support of Merck & Co Inc. - Hikal is also in talks for joint ventures (outside Hikal) with pharmaceutical and agrochemical multinationals (MNCs) where the technology for new molecules would be transferred to the venture by the MNC in exchange for equity. - The company has undertaken several measures to improve the profitability of the Mahad unit. The company has started manufacturing and exporting Isoproturon, which is a forward integration of its main product Para Cumidine. Mahad unit received ISO 9000 certification. 2000 - Hikal Chemical Industries Ltd. has informed the BSE that it will issue one bonus share for every one share held by its shareholders. - Hikal Chemical Industries Ltd. has changed its name to Hikal Ltd. The Change of name reflects the company's intentions to diversify into agro chemicals, pharmaceuticals, information technology and biotech. - Hikal Chemical Industries Ltd., the only global producer of TBZ has been awarded the "British Safety Council" award for world class health, safety and environmental standards at their Taloja plant near Mumbai. 2002 -Appoints Mr Bimal Kishore Raizada as the Additional Director of the company. 2003 -Board approves for the issue of Bonus shares. -Signs agreement with US based pharmaceutical company to supply Gabapentin, a $2 billion anti-depressant that is going off patent. -Enters into Long term supply agreement with a leading Corp protection company in USA for supply of new generation agrochemical. 2004 -Hikal Limited has informed that the Company had applied for delisting of its securities from Ahmedabad Stock Exchange and Pune Stock Exchange. Pune Stock Exchange Ltd. has informed the exchange that it has approved company's request and the equity shares of Hikal Ltd. are delisted from Pune Stock Exchange Ltd. wef January 16, 2004. -Hikal enters into long term agreement with Bayer CropScience AG -Hikal acquires European Pharma Distributor Marsing & Co. -Hikal takes over Danish co 2005 -Hikal Ltd has entered into a long term agreement with a leading American Company, Crompton Corporation, USA, for manufacture & supply of a New Generation crop protection product. -Hikal joins Pfizer's epilepsy drug marketing row in US. 2006 -Hikal Ltd, manufacturer of pharmaceutical and agrochemical ingredients and intermediates, has signed an agreement with Germany's third-largest chemical company Degussa for supplying pharmaceutical intermediates and active pharma ingredients (APIs). -The Registered Office of the Company has been shifted from 6, Nawab Building , 327, Dr. D. N. Road, Fort, Mumbai-400 001 to 717/718 Maker Chamber V, 7th Floor, Nairman Point, Mumbai-400 021. 2011 -The Board has appointed Dr. Wolfgang Welter as an Additional Director. -The prestigious "Hikal Cup" Corporate Tennis Tournament for the year 2011 was played at the Bombay Gymkhana Tennis Courts. 2012 -Hikal Board recommends Final Dividend on the Equity Share Capital @ (60%) Rs. 6/- (Rupees six only) per Equity Share, nominal value of Rs. 10/- each 2013 -Hikal's Pharmaceutical Manufacturing Site in Gujarat, India received US FDA Approval. -Hikal Ltd Board recommends Dividend on Equity Share Capital @ 25% [Rs. 2.50 per equity share, (nominal value of Rs. 10 each)] for financial year 2012-13 -Hikal signs a long term supply agreement with a leading global Biopharmaceutical Company 2014 -Hikal Ltd Board recommends Dividend on Equity Share Capital [Rs. 4.5/- per equity share, (nominal value of Rs. 10/- each) [including interim dividend of 20% (Rs. 2/- per equity share) declared / paid -Hikal Completed successful EDQM Audit of its Bangalore facility 2015 -Hikal has splits its face value from Rs. 10 to Rs. 2 2017 -Hikal won the most coveted ICC Award for Excellence in Human Resource Management in the Chemical Industry for the year 2016. 2018 -The Global Employer Branding Institute and World HRD Congress has conferred Hikal with the `National Best Employer Brands 2018'. -The Company has issued Bonus Shares in the Ratio of 1:2. 2019 -Hikal was conferred with the CSR Leadership Award for Best Corporate Social Responsibility Practices by the World CSR Congress. -Hikal won the coveted Confederation of Indian Industry (CII)'s 'Significant Achievement in HR Excellence' award at the CII National HR Excellence Award. 2021 -"Hikal signs 10 year multi product contract with a leading global pharmaceutical innovator Company". 2024 -The Company Informed regarding Acquisition of 5.73 percent stake in FPEL Ujwal Private Limited